Table 7.

The top three vaccine constructs V1, V2, and V3 made using Beta-defensin, L7/L12 Ribosomal protein, and Gaba protein adjuvants along with the top BCL, HTL, and CTL epitope sequences.

Vaccine	Sequence	Antigenic propensity
V1	GIINTLQKYYCRVRGGRCAVLSCLPKEEQIGKCSTRGRKCCRRKKEAAAKDAALLGGDYGGGSGVDFDSCFFGGGSKTGRNGDMYGGGSSTDDHATGSGGGSGTDGVTGTTGGGSSSDADPTVVGGGSLLVLAALTYGGGSYTCGTSCAVAAYGSFVMDGTVALGGAGAAYKAPRGRIIRLQYLRFAAYTGVSKNGRQLRVSGKAAYASGVLGENGSHMPDGAAYSTSGSAEPTKKVQEQAAYMLVGKYSRNAAAGARAAYLKSWWQRNVETKAVTAAYSGILVDVLMRTSAHRKKGSCGCRCKKPLLLFVFFKKVHINLKQKKTSPLFPLLLVVAKKMTCRLLCALLVLALCCCPSVCVTKKSLWSVRLKKDVPPSSLPKK EKPQCLLLSSGILVDVLMREAAAK	1.06
V2	MSDINKLAETLVNLKIVEVNDLAKILKEKYGLDPSANLAIPSLPKAEILDKSKEKTSFDLILKGAGSAKLTVVKRIKDLIGLGLKESKDLVDNVPKHLKKGLSKEEAESLKKQLEEVGAEVELKEAAAKDAALLGGDYGGGSGVDFDSCFFGGGSKTGRNGDMYGGGSSTDDHATGSGGGSGTDGVTGTTGGGSSSDADPTVVGGGSLLVLAALTYGGGSYTCGTSCAVAAYGSFVMDGTVALGGAGAAYKAPRGRIIRLQYLRFAAYTGVSKNGRQLRVSGKAAYASGVLGENGSHMPDGAAYSTSGSAEPTKKVQEQAAYMLVGKYSRNAAAGARAAYLKSWWQRNVETKAVTAAYSGILVDVLMRTSAHRKKGSCGCRCKKPLLLFVFFKKVHINLKQKKTSPLFPLLLVVAKKMTCRLLCALLVLALCCCPSVCVTKKSLWSVRLKKDVPPSSLPKKEKPQCLLLSSGILVDVLMREAAAK	0.83
V3	MAENPNIDDLPAPLLAALGAADLALATVNDLIANLRERAEETRAETRTRVEERRARLTKFQEDLPEQFIELRDKFTTEELRKAAEGYLEAATNRYNELVERGEAALQRLRSQTAFEDASARAEGYVDQAVELTQEALGTVASQTRAVGERAAKLVGIELEAAAKDAALLGGDYGGGSGVDFDSCFFGGGSKTGRNGDMYGGGSSTDDHATGSGGGSGTDGVTGTTGGGSSSDADPTVVGGGSLLVLAALTYGGGSYTCGTSCAVAAYGSFVMDGTVALGGAGAAYKAPRGRIIRLQYLRFAAYTGVSKNGRQLRVSGKAAYASGVLGENGSHMPDGAAYSTSGSAEPTKKVQEQAAYMLVGKYSRNAAAGARAAYLKSWWQRNVETKAVTAAYSGILVDVLMRTSAHRKKGSCGCRCKKPLLLFVFFKKVHINLKQKKTSPLFPLLLVVAKKMTCRLLCALLVLALCCCPSVCVTKKSLWSVRLKKDVPPSSLPKKEKPQCLLLSSGILVDVLMREAAAK	0.99